JAMA Oncology Study Confirms Oncotype DX Test Effectiveness Across All Racial and Ethnic Groups
• Comprehensive JAMA Oncology review validates that the Oncotype DX Breast Recurrence Score test accurately predicts chemotherapy benefit for breast cancer patients regardless of race or ethnicity.
• The largest real-world SEER registry analysis to date, involving over 171,000 breast cancer patients, provides new evidence supporting the test's consistent performance across diverse populations.
• Despite a 40% higher breast cancer mortality rate among non-Hispanic Black women compared to non-Hispanic White women, the study confirms the test's reliability in guiding precision treatment decisions for all patients.
Cytokinetics and Pyxis Oncology Announce Key Milestones for 2025; CytomX Prioritizes Pipeline
• Cytokinetics anticipates a pivotal year in 2025, focusing on the potential FDA approval and commercial launch of aficamten for obstructive hypertrophic cardiomyopathy (HCM) in the U.S.
• Pyxis Oncology is prioritizing the advancement of PYX-201, a novel antibody-drug conjugate (ADC), with data readouts expected in the second half of 2025 and the first half of 2026.
• CytomX Therapeutics is focusing on its lead program, CX-2051, an EpCAM-targeting PROBODY ADC for advanced metastatic colorectal cancer, with initial Phase 1a data expected in 1H 2025.
Personalized Medicine Biomarkers Market Set to Reach $79.26 Billion by 2034, Driven by Precision Oncology and AI
• The global personalized medicine biomarkers market is projected to grow from $21.95 billion in 2024 to $79.26 billion by 2034, representing a CAGR of 13.7% as demand for precision healthcare solutions increases.
• Treatment selection dominates the market with 50.2% share, while oncology leads indication segments at 36.0%, reflecting the critical role of biomarkers in matching patients to targeted cancer therapies.
• North America currently holds 52.0% of market share, with the U.S. market alone expected to grow at 15.5% CAGR to reach $40.90 billion by 2034, driven by technological advancements and regulatory support.
Aldeyra Therapeutics Resubmits NDA for Reproxalap for Dry Eye Disease Treatment
• Aldeyra Therapeutics has resubmitted its New Drug Application (NDA) to the FDA for reproxalap, targeting the signs and symptoms of dry eye disease (DED).
• The resubmission includes positive Phase 3 clinical trial results demonstrating reproxalap's superiority over vehicle in reducing ocular discomfort.
• The NDA also contains a draft label reflecting acute and chronic activity in reducing dry eye symptoms and ocular redness in clinical trials.
• If approved, reproxalap could be the first DED therapy for chronic use with pivotal data demonstrating acute activity in symptom reduction.
© Copyright 2025. All Rights Reserved by MedPath